During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.